WP
ACHL

Woodline Partners’s Achilles Therapeutics ACHL Stock Holding History

Woodline Partners’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-233,180
Closed -$588K – 841
2022
Q2 		$588K Sell
233,180
-10,116
-4% -$25K 0.01% 559
2022
Q1 		$715K Sell
243,296
-81,091
-25% -$288K 0.01% 499
2021
Q4 		$1.63M Buy
+324,387
New +$1.96M 0.02% 444
2021
Q3 		– Sell
-77,386
Closed -$758K – 752
2021
Q2 		$758K Sell
77,386
-161,436
-68% -$2.19M 0.01% 450
2021
Q1 		$3.95M Buy
+238,822
New +$3.95M 0.09% 214

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
KHCM
Kettle Hill Capital Management New York $399M AUM 10.05% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Woodline Partners's ACHL Position: Q3 2022 in Review

Woodline Partners sold out of Achilles Therapeutics (ACHL) in Q3 2022, closing a stake of 233,180 shares — an estimated $588K sold.

Woodline Partners first reported a position in ACHL in Q1 2021 and held it in 5 quarters. The position peaked at $3.95M in Q1 2021. 28 funds tracked by Wall St. Rank hold ACHL as of Q3 2022.

  • Woodline Partners reported no remaining Achilles Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Woodline Partners sold 233,180 Achilles Therapeutics shares in Q3 2022, an estimated $588K.
  • Woodline Partners first reported a position in Achilles Therapeutics in Q1 2021 and held it in 5 quarters.
  • Woodline Partners's Achilles Therapeutics position peaked at $3.95M in Q1 2021.
  • 28 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q3 2022.

Based on Woodline Partners's 13F filing for Q3 2022, filed 14 Nov 2022.